On June 12, 2023, Heron Therapeutics, Inc. announced that, by mutual agreement with the Company's management, Kimberly Manhard resigned as Executive Vice President, Drug Development of the Company, effective June 6, 2023. Additionally, effective as of June 6, 2023, William Forbes joined the Company as Executive Vice President, Chief Development Officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.965 USD | -1.17% | +2.04% | +76.47% |
May. 07 | Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.47% | 452M | |
+29.26% | 49.46B | |
+0.54% | 42.58B | |
+48.94% | 42.49B | |
-5.26% | 29.09B | |
+12.24% | 26.61B | |
-24.12% | 18.64B | |
+7.57% | 13.16B | |
+31.96% | 12.55B | |
+24.12% | 12.1B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Announces Management Changes